APA (7th ed.) Citation

Gillison, M. L., Ringash, J., Galvin, J., Yao, M., Koyfman, S. A., Blakaj, D. M., . . . Harris, J. (2019). Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet, 393(10166), 40. https://doi.org/10.1016/S0140-6736(18)32779-X

Chicago Style (17th ed.) Citation

Gillison, Maura L., et al. "Radiotherapy Plus Cetuximab or Cisplatin in Human Papillomavirus-positive Oropharyngeal Cancer (NRG Oncology RTOG 1016): A Randomised, Multicentre, Non-inferiority Trial." Lancet 393, no. 10166 (2019): 40. https://doi.org/10.1016/S0140-6736(18)32779-X.

MLA (9th ed.) Citation

Gillison, Maura L., et al. "Radiotherapy Plus Cetuximab or Cisplatin in Human Papillomavirus-positive Oropharyngeal Cancer (NRG Oncology RTOG 1016): A Randomised, Multicentre, Non-inferiority Trial." Lancet, vol. 393, no. 10166, 2019, p. 40, https://doi.org/10.1016/S0140-6736(18)32779-X.